我国曾是乙型肝炎病毒（HBV）感染的高发地区，过去30多年我国在乙型肝炎防控领域取得了举世瞩目的成就。但我国现存乙型肝炎感染人数仍然众多，因此在提高诊断率和治疗率等方面仍面临巨大挑战。本文简要综述我国在乙型肝炎防治进展、挑战及亟需进一步加强的措施。

2020年我国乙型肝炎流行病学调查发现的HBsAg阳性者中，15～69岁HBsAg阳性者的总体自我知晓率仅为41.3%，男性知晓率低于女性；60～69岁年龄段知晓率低于其他年龄段，农村地区知晓率低于城市，人均 地区生产总值 ...

Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...

在全球范围内，慢性乙型肝炎（乙肝）一直是威胁人类健康的重大公共卫生问题。据世界卫生组织统计，全球约有3亿慢性乙肝病毒感染者，其我国患者占比近三分之一。长期以来，乙肝患者面临无法根治、需终身用药的困境，而近期葛兰素史克（GSK）的一则重磅消息，为这一群体带来了希望。

Despite numerous treatment advances, chronic hepatitis B virus (HBV) infection remains a largely incurable disease impacting more than 290 million people worldwide. All patients with chronic HBV ...

As part of their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) can establish an infection in liver cells, researchers led by teams at Memorial Sloan ...

The following vaccines are approved by the Food and Drug Administration (FDA) to prevent hepatitis B as well as other conditions: One U.S. study following trends in hepatitis B infection over a ...

Antiviral treatments are readily available in the U.S. Both current HBV-positive patients and those with previous HBV exposure, including those with immunity to HBV, are at risk of virus ...

PBGENE-HBV, which comprises an ARCUS-encoding mRNA ... Precision expects to expand the study to the U.S. and U.K. and continue accelerating recruitment and evaluation of a genetically diverse ...